Skip to content

Plasma or serum metabolomic analysis

Full Image of the Metabolic Profile

Our metabolomic platform performs a thorough analysis with more than 50 blood metabolites, including the traditional lipid panel, advanced characterization of lipoproteins, inflammatory markers and fatty acid profile. This information provides a complete picture of the individual’s metabolic profile.

Liposcale®, an advanced test to prevent cardiovascular risk

Liposcale® has been developed to determine both the basic lipid profile composed of total cholesterol, LDL, HDL, non-HDL and triglycerides, as well as an advanced lipoprotein profile that includes the lipid composition, particle size and concentration of 9 subclasses of LDL and HDL VLDL lipoproteins.

How to get started

Serum or plasma sample:

Volume – 250 μl

Accelerate research results with our automated technology

Request the quote and receive the submission form.

Send the samples to our centre where they will be analysed.

Receive the results of metabolomic characterization and contact us if you have any doubts.

Our Service

Robustness and reproducibility

Quantitative and comparable results in different studies.

Quick scan

We have a fully automated technology platform

Personalized care

We facilitate the interpretation of the data to each researcher

Our Added Value

Quality

Biosfer Teslab is ISO 9001 and ISO 13485 certified.

Experience

Our research team is available to answer any questions about data and analysis.

Data Analysis

We have population databases that can be used to compare normal values.

Are you interested in our services?

ACCIÓ GRANT

BIOSFER TESLAB, SL with the support of ACTION in the frame of the Operative Program FEDER Catalonia 2014-2020 has carried out the “DEVELOPMENT And VALIDATION OF ADVANCED DIAGNOSTIC TEST Of INFLAMMATION And  INSULIN RESISTANCE FOR THE IMPROVEMENT OF  CARDIOVASCULAR RISK USING NUCLEAR MAGNETIC RESONANCE”  (RD15-1-0013).

Biosfer Teslab, along the project, has developed a system of prediction, using of advanced prediction tests, with the aim to improve the evaluation of cardiovascular risk and to identify those individuals with residual cardiovascular risk that would remain undiagnosed with classical risk factors.

In particular, the company has developed a glycoprotein test and a LMWM test - that includes, branched amino acids -, as they have been identified as inflammatory markers and involved in insulin resistance processes, respectively.

The Agency for the Competitiveness of the Company, ACTION, aiding to industrial research centers and experimental development, has granted Biosfer Teslab with an amount of 67,728.97 €.

This aid is programmed in the axis 1, "Boost research, technological development and innovation", specific objective OE 1.2.2, "Transfer and spreading of technology and cooperation between companies and universities or other research centers", line of action "Collaborative R+D projects" under the framework of the FEDER Operational Program of Catalonia 2014-2020